TD Cowen Boosts GoodRx (NASDAQ:GDRX) Price Target to $16.00

GoodRx (NASDAQ:GDRX) had its target price boosted by TD Cowen from $14.00 to $16.00 in a research note published on Thursday morning, Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also issued reports on the stock. Wells Fargo & Company raised shares of GoodRx from an equal weight rating to an overweight rating and lifted their target price for the company from $7.50 to $10.00 in a research note on Monday, March 25th. KeyCorp upgraded shares of GoodRx from a sector weight rating to an overweight rating and set a $9.00 price target on the stock in a report on Wednesday, April 10th. SVB Leerink began coverage on shares of GoodRx in a report on Monday, February 26th. They issued an outperform rating and a $8.00 price objective for the company. Truist Financial raised their target price on GoodRx from $7.50 to $8.00 and gave the company a hold rating in a report on Friday, March 1st. Finally, UBS Group upped their price target on GoodRx from $5.00 to $8.00 and gave the stock a neutral rating in a research note on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, GoodRx currently has an average rating of Moderate Buy and a consensus price target of $8.95.

GoodRx Trading Down 7.2 %

GDRX opened at $7.48 on Thursday. GoodRx has a 12-month low of $4.14 and a 12-month high of $9.37. The company has a debt-to-equity ratio of 1.02, a quick ratio of 6.29 and a current ratio of 6.29. The stock has a fifty day moving average of $6.96 and a 200-day moving average of $6.47.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Thursday, February 29th. The company reported $0.02 EPS for the quarter, hitting analysts’ consensus estimates of $0.02. The firm had revenue of $196.64 million during the quarter, compared to analyst estimates of $195.59 million. GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. As a group, research analysts predict that GoodRx will post 0.23 EPS for the current year.

Institutional Investors Weigh In On GoodRx

A number of hedge funds and other institutional investors have recently bought and sold shares of GDRX. Beacon Capital Management LLC bought a new stake in shares of GoodRx during the first quarter worth $28,000. Citigroup Inc. lifted its position in GoodRx by 301.7% during the 3rd quarter. Citigroup Inc. now owns 7,997 shares of the company’s stock worth $45,000 after buying an additional 6,006 shares in the last quarter. Mackenzie Financial Corp bought a new stake in GoodRx during the 3rd quarter worth about $68,000. Gerber LLC acquired a new stake in GoodRx in the 4th quarter valued at about $75,000. Finally, Innealta Capital LLC bought a new position in shares of GoodRx in the fourth quarter worth about $91,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.